Please complete the CAPTCHA to continue
@fastercures.org
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Bernard Munos is listed as Senior Fellow at Faster Cures, a Center of the Milken Institute at FasterCures, A Center of the Milken Institute, a company with 24 employees, based in Indianapolis, Indiana, United States. AeroLeads shows a work email signal at fastercures.org and a matched LinkedIn profile for Bernard Munos.
Bernard Munos previously worked as Chief Apostle, breakthrough innovation at Innothink Center For Research In Biomedical Innovation and Senior Fellow at Fastercures, A Center Of The Milken Institute. Bernard Munos holds Mba, Business Strategy, General Management from Stanford University Graduate School Of Business.
This section adds company-level context without repeating Bernard Munos's masked contact details.
AeroLeads found 1 current-domain work email signal for Bernard Munos. Compare company email patterns before reaching out.
The pharmaceutical industry is in transition. More and better drugs are reaching the market than at any time since WWII. Yet, challenges remain that will likely reshape the industry in the decade ahead. They include:• A massive shift of market share toward generics, which now fill 90% of prescriptions in the US—up from 50% in 2000• New technologies which are digitizing science and medicine• The emergence of mHealth technology which is slashing the cost of data collection and allowing the capture of rich, longitudinal data sets• The growing engagement of patients in data collection, and their control over the use of that data• The concern about drug prices which is pushing Americans of both parties to press for government action• New players such as virtual companies, academic entrepreneurs, patient organizations, and venture philanthropists, that are pursuing various models for doing drug R&D on a shoestringIt is hard to predict the joint impact of these forces on the pharmaceutical industry. Many industry metrics are worrisome: over 75% of the sales of the top 22 companies come from drugs that are more than 10 years old; seven of the top thirteen pharma companies have seen a drug revenue contraction since 2010; six large companies have disappeared to M&A since 2000; and the increasingly challenging competitive environment makes it difficult for mediocre drugs to achieve commercial success, putting less innovative companies in a precarious situation.While scientific and technological advances point to the dawn of a hyperinnovation age, the legacy innovation models used by many pharmaceutical companies are ill-suited to harness innovation occurring outside their zones of comfort. This may cause turmoil ahead and culminate in a surge of new players which will rise to the top of the industry, powered by nimbler and thriftier R&D models.InnoThink was created to help biomedical research organizations become better innovators.
Listed skills include Pharmaceutical Industry, Pharmaceutics, Fda, Science, and 34 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
InnoThink works with companies, biomedical research organizations, think tanks, and patient organizations to help design and implement strategies that foster greater innovation.
FasterCures is an "action tank" dedicated to speeding the development of new therapies by eliminating the obstacles that thwart, slow, or deter innovation. As a Senior Fellow, I help with projects aimed at fostering a more favorable climate for innovation, including better policies, regulations, funding models, and risk-mitigation tools.
Glenmark is an Indian pharmaceutical company with worldwide revenues of about US$1.6 billion. For the last 10 years, it has invested heavily in innovative R&D at both its center for biological research in Switzerland, and for small molecule research in India. In 2019, it spun off its pipeline of multispecific monoclonal antibodies into a new company, Ichnos.
Paris Area, France
Stellate (formerly Amabiotics) is a biopharmaceutical company that mines the microbiome for molecules that are active in humans. Its lead compound, which mitigates mitochondrial dysfunction, has the potential to be a first-in-class therapy for Parkinson’s Disease. Amabiotics was co-founded by Antoine Danchin, a mathematician turned biologist who is a.
Scientist.com is an e-commerce platform that lets scientists source the products and services they need at attractive prices, while ensuring compliance with their organizations’ procurement rules. It counts 24 of the top 30 pharmaceutical companies as clients, along with the National Institutes of Health. It ranked 63rd in the Financial Times' 2020 list of.
Open Source Pharma is a nonprofit organization that aims at harnessing the creativity of the scientific community ("the global brain") to bring innovation to diseases and populations that haven't see much of it – i.e., rare diseases and the diseases of poverty. It intends to become a virtual, networked component of the global drug R&D ecosystem where.
Aseda has developed a unique technology to perform rapid (1-day) low-cost toxicology assessment of small molecules—a task that typically takes months and millions of dollars
Science Translational Medicine is a journal of the American Association for the Advancement of Science (AAAS). It reports on cutting-edge biomedical research, its translation into novel therapies, as well as their policy and societal implications.
The ACDRS is a nonprofit course established by UCSF’s School of Pharmacy in collaboration with the FDA and a network of universities and pharmaceutical companies. It provides continuing education to these organizations.
Greater New York City Area
Ichnos is a NYC-based spin-off of Glenmark Pharmaceuticals. It was born out of Glenmark's innovative R&D at its research center for biologics in Switzerland. Ichnos’ clinical research pipeline includes three new biological entities for oncology and autoimmune diseases. Its drug candidates were designed with the company's proprietary BEAT® (Bispecific.
Ghent, Belgium
Ontoforce has developed a much-needed technology to easily connect any number of (often incompatible) databases, so that they can be queried at once. Its recently-launched product, Disqover(R), has already been licensed by several large pharmaceutical companies
The “Drug Forum” is a group of leaders organized under the aegis of the National Academy of Medicine to address emerging issues related to drug R&D—including economic, technological, and regulatory challenges. Its members comprise leaders from industry, NIH, FDA, the academic community, and patient advocacy groups
I am the author of The Innovation Chatroom, a blog about biomedical innovation and related topics such as R&D productivity, regulation, and the cost of new drugs
ACRES is a global, private, non-profit, non-governmental network of scientists from leading institutions, who are building a high-capacity network for clinical research. Its goal is to offer sites that can dependably handle the growing volume of clinical trials while reducing the cost and time required to bring new treatments to patients.
New York City
Medidata is the leading provider of cloud-based software for the recruitment, management and analysis of clinical trials. Its customers include 22 of the top 25 pharmaceutical companies
The NCATS Advisory Council provides guidance and recommendations to the Secretary of Health and Human Services, the NIH director and to the NCATS director on the Center's initiatives, policies and programs. It also conducts a second-level review of scientific grant applications.
The Cures Acceleration Network Review Board advises and provides recommendations to the NCATS director on the policies, programs and procedures for carrying out the duties of his Office, and on identifying significant barriers to the successful translation of basic science into clinical applications.
New York City
Transparency Life Sciences is one of the first companies that saw the potential of combining patient input with mHealth technologies to transform clinical research.
Poliwogg is a crowdfunding platform that helps fund young transformational biomedical companies, a segment rich in opportunties but under-served by traditional funding channels. It aims at providing capital to companies that are too big for grants, yet too small for venture capital -- the stage commonly referred to as "the valley of death". It pools.
Solve ME/CFS is a non-profit organization that is dedicated to accelerating the development of treatments for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome.
The Law and Bioscience Project matches UC Hastings students with leaders of the IP and bioscience community to work on research topics that explore some of bioscience law’s most challenging issues
Thiel Fellowships bring together some of the world’s most creative and motivated young people, and helps them bring their most ambitious ideas and projects to life. "If you want to change the world, leave it to the kids... They are pretty good at it." (Samir Brahmachari, former Chief Scientist of India)
The UC Berkeley BioExec Institute provides executive education programs to the leaders of the life science industry
US, Portugal, Austria, France
I worked at Eli Lilly for 30 years – first as international business executive in its animal health division (18 years), and then as a corporate pharmaceutical strategy advisor focused on breakthrough innovation and the redesign of drug R&D (12 years). The first part of my career involved positions of increasing responsibilities in international marketing.
Other employees you can reach at fastercures.org. View company contacts for 24 employees →
Jeongyeon Shim
Colleague at Fastercures, A Center Of The Milken Institute
New Alexandria, Virginia, United States, United States
View →
HC
Hadly Clark, Mhsa
Colleague at Fastercures, A Center Of The Milken Institute
Washington DC-Baltimore Area, United States
View →
SH
Sung Hee Choe
Colleague at Fastercures, A Center Of The Milken Institute
New York City Metropolitan Area, United States
View →
RP
Raymond P.
Colleague at Fastercures, A Center Of The Milken Institute
Washington, District Of Columbia, United States, United States
View →
SK
Sue Kahn
Colleague at Fastercures, A Center Of The Milken Institute
Brookline, Massachusetts, United States, United States
View →
http://www.agroparistech.fr/Presentation-of-AgroParisTech.html
Quick answers generated from the profile data available on this page.
Bernard Munos works for FasterCures, A Center of the Milken Institute.
Bernard Munos is listed as Senior Fellow at Faster Cures, a Center of the Milken Institute at FasterCures, A Center of the Milken Institute.
AeroLeads has found 1 work email signal at @fastercures.org for Bernard Munos at FasterCures, A Center of the Milken Institute.
Bernard Munos is based in Indianapolis, Indiana, United States while working with FasterCures, A Center of the Milken Institute.
Bernard Munos has worked for Innothink Center For Research In Biomedical Innovation, Fastercures, A Center Of The Milken Institute, Glenmark Pharmaceuticals, Stellate Therapeutics (Fka Amabiotics), and Scientist.Com.
Bernard Munos's colleagues at FasterCures, A Center of the Milken Institute include Jeongyeon Shim, Hadly Clark, Mhsa, Sung Hee Choe, Raymond P., and Sue Kahn.
You can use AeroLeads to view verified contact signals for Bernard Munos at FasterCures, A Center of the Milken Institute, including work email, phone, and LinkedIn data when available.
Bernard Munos holds Mba, Business Strategy, General Management from Stanford University Graduate School Of Business.
Bernard Munos is listed with skills including Pharmaceutical Industry, Pharmaceutics, Fda, Science, Drug Discovery, R&D, Clinical Development, and Lifesciences.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contactsCheck these profiles if this is not the Bernard Munos you were looking for.
